Angiogenesis does not predict clinical response to doxorubicin monotherapy in patients with locally advanced breast cancer.
Paulsen
T
T
Aas
T
T
Børresen
A L
AL
Varhaug
J E
JE
Lønning
P E
PE
Akslen
L A
LA
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D015415:Biomarkers; D001943:Breast Neoplasms / Q000098:blood supply* / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D016158:Genes, p53; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D009154:Mutation; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic; D011237:Predictive Value of Tests; D016159:Tumor Suppressor Protein p53 / Q000032:analysis / Q000235:genetics; D014841:von Willebrand Factor / Q000032:analysis
D000903:Antibiotics, Antineoplastic; D015415:Biomarkers; D016159:Tumor Suppressor Protein p53; D014841:von Willebrand Factor; D004317:Doxorubicin